Literature DB >> 10600299

Prognostic significance of p53 and p21(waf1/cip1) immunoreactivity in epithelial cancers of the ovary.

B A Werness1, A N Freedman, M S Piver, M Romero-Gutierrez, E Petrow.   

Abstract

OBJECTIVES: Theprognostic value of p53 expression in epithelial ovarian cancer remains unresolved. We hypothesized that prognosis may relate more to expression of p21(waf1/cip1), the major downstream effector of p53, which can also be induced through p53-independent mechanisms. We therefore studied the relationship of p53 and p21(waf1/cip1) expression in epithelial ovarian cancers to clinicopathological variables and prognosis.
METHODS: Fixed, embedded tumors from 85 patients with untreated, primary epithelial ovarian cancer were immunostained with antibodies to p53 and p21(waf1/cip1). Expression was correlated with clinicopathological features and prognosis. Survival curves were calculated by the Kaplan-Meier method and compared using the log-rank test for p53, p21(waf1/cip1), and all combinations of expression of the two markers.
RESULTS: Sixty-two percent of tumors expressed p53, and 42% expressed p21(waf1/cip1). There was no correlation between p53 and p21(waf1/cip1) expression. Advanced stage, grade, age >/=50, and p53 expression were associated with worse disease-free survival. Patients whose tumors were p53(+)/waf1(-), however, had a particularly strong association with poorer disease-free survival when compared with other combinations of p53 and p21(waf1/cip1) expression (P = 0.003). Neither p53, nor p21(waf1/cip1), nor combinations of expression were independently related to survival when histology, age, stage, and differentiation were considered.
CONCLUSIONS: p53 expression in the absence of p21(waf1/cip1) expression is a better marker of poor prognosis than either p53 or p21(waf1/cip1) expression status alone in univariate analysis. Absence of independent prognostic significance may be related to the paucity of early stage cases in the current study. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10600299     DOI: 10.1006/gyno.1999.5601

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  3 in total

1.  Cyclin-dependent kinase inhibitors CIP1 (p21) and KIP1 (p27) in ovarian cancer.

Authors:  Annette Schmider-Ross; Olaf Pirsig; Elisabeth Gottschalk; Carsten Denkert; Werner Lichtenegger; Angela Reles
Journal:  J Cancer Res Clin Oncol       Date:  2005-11-19       Impact factor: 4.553

2.  Expression of apoptosis-related proteins in endometriomas and benign and malignant ovarian tumours.

Authors:  Raffaèle Fauvet; Christophe Poncelet; Danièle Hugol; Anne Lavaur; Gérard Feldmann; Emile Daraï
Journal:  Virchows Arch       Date:  2003-05-20       Impact factor: 4.064

3.  Carbonyl reductase as a significant predictor of survival and lymph node metastasis in epithelial ovarian cancer.

Authors:  M Umemoto; Y Yokoyama; S Sato; S Tsuchida; F Al-Mulla; Y Saito
Journal:  Br J Cancer       Date:  2001-09-28       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.